Abstract
Aim: In the recent years, evidences have been accumulated indicating that carcinogen/drug metabolizing genes and DNA-repair genes may play an important role in determining individual susceptibility to cancer & treatment outcomes. Pharmacogenetic variability associated with the drug metabolizing enzymes could be a major determinant of variations in treatment outcomes. The present study was designed to understand effect of Pharmacogenetic variability associated with Cytochrome P4502C19 (CYP2C19) on treatment outcomes in cancer patients.
Sign-in/Register to access full text options 
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have
Schedule a callDisclaimer: All third-party content on this website/platform is and will remain the property of their respective owners and is provided on "as is" basis without any warranties, express or implied. Use of third-party content does not indicate any affiliation, sponsorship with or endorsement by them. Any references to third-party content is to identify the corresponding services and shall be considered fair use under The CopyrightLaw.
